Yong Sik Kim

Yong Sik Kim

Auto-generated profile, based on publicly available information

Yong Sik Kim

Department of Psychiatry, Uijeongbu Eulji Medical Center, Uijeongbu, Korea

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2021 in Pharmacopsychiatry
Verified
Journal Article
Closed access
PDF file
JLJose de Leon
Jose de Leon
GSGeorgios Schoretsanitis
Georgios Schoretsanitis
RSRobert L. Smith
Robert L. Smith
EMEspen Molden
Espen Molden
ASAnssi Solismaa
Anssi Solismaa
DMDaniel Mueller
Daniel Mueller
This international guideline proposes improving clozapine package inserts worldwide by using ancestry-based dosing and titration. Adverse drug reaction (ADR) databases suggest that clozapine is the third most toxic drug in the United States (US), and it produces four times higher worldwide pneumonia mortality than that by agranulocytosis or myocarditis. For trough steady-state clozapine serum concentrations, the therapeutic reference range is narrow, from 350 to 600 ng/mL with the potential for toxicity and ADRs as concentrations increase. Clozapine is mainly metabolized by CYP1A2 (female non-smokers, the lowest dose; male smokers, the highest dose). Poor metabolizer status through phenotypic conversion is associated with co-prescription of inhibitors (including oral contraceptives and valproate), obesity, or inflammation with C-reactive protein (CRP) elevations. The Asian population (Pakistan to Japan) or the Americas’ original inhabitants have lower CYP1A2 activity and require lower clozapine doses to reach concentrations of 350 ng/mL. In the US, daily doses of 300–600 mg/day are recommended. Slow personalized titration may prevent early ADRs (including syncope, myocarditis, and pneumonia). This guideline defines six personalized titration schedules for inpatients: 1) ancestry from Asia or the original people from the Americas with lower metabolism (obesity or valproate) needing minimum therapeutic dosages of 75–150 mg/day, 2) ancestry from Asia or the original people from the Americas with average metabolism needing 175–300 mg/day, 3) European/Western Asian ancestry with lower metabolism (obesity or valproate) needing 100–200 mg/day, 4) European/Western Asian ancestry with average metabolism needing 250–400 mg/day, 5) in the US with ancestries other than from Asia or the original people from the Americas with lower clozapine metabolism (obesity or valproate) needing 150–300 mg/day, and 6) in the US with ancestries other than from Asia or the original people from the Americas with average clozapine metabolism needing 300–600 mg/day. Baseline and weekly CRP monitoring for at least four weeks is required to identify any inflammation, including inflammation secondary to clozapine rapid titration.

6 February 2008 in Bipolar Disorders
Verified
Journal Article
Closed access
PDF file
YAYong Min Ahn
Yong Min Ahn
JCJaeseung Chang
Jaeseung Chang
YJYeon Ho Joo
Yeon Ho Joo
SKSeong Chan Kim
Seong Chan Kim
KLKyu Young Lee
Kyu Young Lee
YKYong Sik Kim
Yong Sik Kim

1 June 2007 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
PDF file
MRMyoung-Sun Roh
Myoung-Sun Roh
MSMyoung Suk Seo
Myoung Suk Seo
YKYeni Kim
Yeni Kim
SKSe Hyun Kim
Se Hyun Kim
WJWon Je Jeon
Won Je Jeon
YKYong Sik Kim
Yong Sik Kim
Glycogen synthase kinase 3 (GSK3) was recently suggested to be a potential target of psychotropics used in psychiatric illnesses such as schizophrenia and bipolar disorder. Relevant studies have found that antipsychotic drugs regulate GSK3 activity via an increase in either inhibitory serine phosphorylation or amount of GSK3 after acute or subchronic treatment. Recent evidence shows that GSK3 is regulated by dopaminergic or serotonergic systems implicated in the pathophysiology and treatment mechanisms of schizophrenia and bipolar disorder. Therefore, antipsychotics may regulate GSK3 via antagonizing dopaminergic or serotonergic activity. However, the signaling pathway that is involved in GSK3 regulation by dopaminergic or serotonergic systems has not been well established. Haloperidol is a typical antipsychotic with potent dopamine D2 receptor antagonism. Clozapine is an atypical antipsychotic with potent serotonin 5HT2 receptor antagonism. We injected rats with haloperidol or clozapine and examined the phosphorylation and amount of GSK3α/β and its well-known upstream regulators Akt and Dvl in the rat frontal cortex by Western blotting. Both haloperidol and clozapine induced Ser21/9 phosphorylation of GSK3GSK3α/β. Haloperidol increased the Ser473 phosphorylation of Akt transiently, whereas clozapine maintained the increase for 1 h. Haloperidol did not affect the phosphorylation and amount of Dvl, whereas clozapine increased both phosphorylation and the amount of Dvl. Our results suggest that GSK3 activity may be regulated by both typical and atypical antipsychotics and that Akt or Dvl, depending on the D2- or 5HT2- receptor antagonism properties of typical and atypical antipsychotics, mediate the regulation differently.

28 June 2011 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
MKMin Kyung Kim
Min Kyung Kim
SKSe Hyun Kim
Se Hyun Kim
HYHyun Sook Yu
Hyun Sook Yu
HPHong Geun Park
Hong Geun Park
UKUng Gu Kang
Ung Gu Kang
YKYong Sik Kim
Yong Sik Kim
Clozapine is an antipsychotic drug that has a greater efficacy than other medications in some contexts, especially for the treatment of treatment-resi

12 June 2002 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
JKJong‐Hoon Kim
Jong‐Hoon Kim
HJHee Yeon Jung
Hee Yeon Jung
UKUng Gu Kang
Ung Gu Kang
SJSeong Hoon Jeong
Seong Hoon Jeong
YAYong Min Ahn
Yong Min Ahn
YKYong Sik Kim
Yong Sik Kim

4 August 2010 in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
Verified
Journal Article
Closed access
PDF file
SKSe Hyun Kim
Se Hyun Kim
JSJoo Yun Song
Joo Yun Song
EJEun‐Jeong Joo
Eun‐Jeong Joo
KLKyu Young Lee
Kyu Young Lee
YAYong Min Ahn
Yong Min Ahn
YKYong Sik Kim
Yong Sik Kim